Méhnyakrák: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• TP53 2
• PD-1 19
• PD-L1 12
• PI3K 3
• AKT 1
• CTLA-4 7
• HER2 9
• CTNNB1 0
• mTOR 0
• STAT3 0
• VEGF 3
• EGFR 2
• MYC 0
• MAPK 0
• PTEN 2
• NRF2 1
• PIK3CA 3
• ERK 0
• PARP 0
• AMPK 0
• JAK 0
• TROP2 4
• YAP 0
• BRCA1 2
• GPX4 0
• HIF-1 0
• IL-6 0
• TNF 0
• FOXP3 0
• KRAS 0
• B7-H3 3
• BCL-2 0
• BRCA2 2
• HER3 1
• JNK 0
• MMP-9 0
• STING 0
• STK11 0
• AXL 0
• CD47 0
• COX-2 0
• EZH2 0
• FAK 1
• HDAC 0
• HMGB1 0
• PPAR 0
• PRAME 0
• ATM 0
• CD40 0
• CXCR4 0
• IDH 1
• LAG-3 0
• METTL3 0
• NF1 0
• NOTCH1 0
• PKM2 0
• PRMT5 0
• SHP2 0
• SIRT1 0
• ALK 0

7+ intézményből 7, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-ERC

  Cervical Cancers Escaping HPV Screening: Decoding HPV-Independent Carcinogenesis through Multi-Omics Profiling (ESCAPE-HPV)

  Karolinska Institutet· Stockholm, Svédország· EU contribution 1 493 450 EUR· until 2031. dec.

• European Commission (Horizon Europe) · HORIZON-RIA

  Offering combined HPV vaccination and HPV test-based cervical screening to vulnerable populations. A hybrid efficacy and implementation study. (HPV-FASTER-Implement)

  Institut National de la Sante Et de la Recherche Medicale· Paris, Franciaország· EU contribution 6 602 445 EUR· until 2029. dec.· 8 countries

• European Commission (Horizon Europe) · HORIZON-JU-RIA

  Understanding vaccination hesitancy and evaluating single dose and gender-neutral vaccination for improving uptake of HPV vaccines in West and East Africa. (IMPROVE-HPV)

  Institut Catala D'oncologia· Hospitalet de Llobregat, Spanyolország· EU contribution 3 613 288 EUR· until 2028. máj.· 4 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Engineering B cells to fight cancer (EngineerBcells)

  Tel Aviv University· Tel Aviv, Izrael· EU contribution 1 996 250 EUR· until 2027. szept.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-RIA

  Dual screening by Spectral Artificial Visual Examination (SAVE) for Female Genital Schistosomiasis (FGS) and cervical cancer. Digital, new, low-cost, and simple screening and training. (DUALSAVE-FGS)

  Oslo Universitetssykehus Hf· Oslo, Norvégia· EU contribution 7 984 441 EUR· until 2027. aug.· 6 countries

5 of 6 running projects, newest first. Listed amounts together: 23,2 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors

  NCT06975410· Yuhan Corporation· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 28
• Organoids 10
• Mendelian Randomization Analysis 13
• CRISPR-Cas Systems 21
• Gene Expression Profiling 70
• Sequence Analysis, RNA 5
• Whole Genome Sequencing 1
• Exome Sequencing 3
• Proteomics 18
• Metabolomics 9
• Mass Spectrometry 4
• Flow Cytometry 25
• Immunohistochemistry 46
• Liquid Biopsy 8
• Circulating Tumor DNA 6
• Xenograft Model Antitumor Assays 66
• Positron-Emission Tomography 14
• Magnetic Resonance Imaging 92
• Machine Learning 63
• Deep Learning 50
• Cohort Studies 82
• Genome-Wide Association Study 14

• FMCerNet: frequency-aware multi-label learning for fine-grained cervical cytology screening.

  Bioinformatics, 2026. okt.

• Deciphering the role of microplastics-related molecular signatures in cervical cancer progression: Transcriptomic analysis and diagnostic model development.

  Biochem Biophys Res Commun, 2026. szept.

• Comprehensive Analysis of Cuproptosis-Related Genes According to Cancer Stage and Their Prognostic Value in Cervical Cancer.

  Int J Mol Sci, 2026. aug.

• Weighted Gene Co-Expression Network Analysis and Machine Learning Reveal that USP1 Drives Lipid Metabolism and Macrophage Polarization in Cervical Cancer Cells.

  Reprod Sci, 2026. aug.

• Label-free cervical cancer detection in tissue samples using Raman spectroscopy combined with machine learning technology.

  Anal Methods, 2026. aug.

• A prognostic immune signaling-related lncRNA-circRNA-mRNA network model for cervical cancer using machine learning.

  Biochem Biophys Res Commun, 2026. júl.

• Preoperative PET/CT phenotype of gastric-type endocervical adenocarcinoma: integrated morphological, metabolic, serological, and explainable machine-learning analysis.

  Eur J Nucl Med Mol Imaging, 2026. júl.

• [Interpretable machine learning models for preoperative precision prediction of perineural invasion in cervical cancer to support treatment decision: a multicenter retrospective study].

  Nan Fang Yi Ke Da Xue Xue Bao, 2026. júl.

• A rapid detection of early-stage cervical cancer using nucleus and cytoplasm-based machine learning-driven refractive index surface plasmon resonance biosensor with ZnO-ag efficient materials.

  Spectrochim Acta A Mol Biomol Spectrosc, 2026. júl.

• AI-assisted Radiomic Model for Cervical Cancer Recurrence Prediction: A Multicenter Retrospective Study with Experimental Validation.

  Radiol Imaging Cancer, 2026. júl.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.